IE
RGLS

Israel Englander’s Regulus Therapeutics RGLS Stock Holding History

Israel Englander’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,192,158
Closed -$3.46M – 6315
2024
Q4 		$3.46M Buy
2,192,158
+900,743
+70% +$1.38M ﹤0.01% 3166
2024
Q3 		$2.03M Buy
1,291,415
+75,834
+6% +$125K ﹤0.01% 3693
2024
Q2 		$2.17M Sell
1,215,581
-659,645
-35% -$1.53M ﹤0.01% 3476
2024
Q1 		$5.4M Buy
+1,875,226
New +$3.06M ﹤0.01% 2786
2022
Q2 		– Sell
-4,889
Closed -$15K – 7417
2022
Q1 		$15K Buy
+4,889
New +$12.7K ﹤0.01% 6682
2020
Q4 		– Sell
-4,950
Closed -$25 – 5522
2020
Q3 		$25 Sell
4,950
-407
-8% -$2.68K ﹤0.01% 4336
2020
Q2 		$37K Buy
+5,357
New +$35.1K ﹤0.01% 4068
2018
Q3 		– Sell
-202
Closed -$16K – 4210
2018
Q2 		$16K Sell
202
-715
-78% -$59.2K ﹤0.01% 3737
2018
Q1 		$79K Sell
917
-2,620
-74% -$351K ﹤0.01% 3500
2017
Q4 		$441K Buy
3,537
+223
+7% +$28.2K ﹤0.01% 3155
2017
Q3 		$497K Sell
3,314
-605
-15% -$76.1K ﹤0.01% 2845
2017
Q2 		$463K Buy
+3,919
New +$654K ﹤0.01% 2839
2017
Q1 		– Sell
-3,135
Closed -$847K – 3794
2016
Q4 		$847K Buy
3,135
+2,750
+714% +$894K ﹤0.01% 2343
2016
Q3 		$152K Buy
+385
New +$158K ﹤0.01% 3049
2016
Q2 		– Sell
-1,556
Closed -$1.29M – 3502
2016
Q1 		$1.29M Buy
1,556
+1,111
+250% +$884K ﹤0.01% 2041
2015
Q4 		$465K Buy
+445
New +$446K ﹤0.01% 2680
2015
Q3 		– Sell
-203
Closed -$266K – 3684
2015
Q2 		$266K Buy
+203
New +$328K ﹤0.01% 2934
2015
Q1 		– Sell
-140
Closed -$269K – 4010
2014
Q4 		$269K Buy
+140
New +$249K ﹤0.01% 3423
2014
Q2 		– Sell
-958
Closed -$1.04M – 3785
2014
Q1 		$1.04M Sell
958
-249
-21% -$276K ﹤0.01% 2199
2013
Q4 		$1.07M Buy
1,207
+165
+16% +$142K ﹤0.01% 2240
2013
Q3 		$1.18M Buy
+1,042
New +$1.23M ﹤0.01% 2000

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's RGLS Position: Q1 2025 in Review

Israel Englander sold out of Regulus Therapeutics (RGLS) in Q1 2025, closing a stake of 2,192,158 shares — an estimated $3.46M sold.

Israel Englander first reported a position in RGLS in Q3 2013 and held it in 21 quarters. The position peaked at $5.4M in Q1 2024. 75 funds tracked by Wall St. Rank hold RGLS as of Q1 2025.

  • Israel Englander reported no remaining Regulus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 2,192,158 Regulus Therapeutics shares in Q1 2025, an estimated $3.46M.
  • Israel Englander first reported a position in Regulus Therapeutics in Q3 2013 and held it in 21 quarters.
  • Israel Englander's Regulus Therapeutics position peaked at $5.4M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.